PRINCETON, N.J. --(BUSINESS WIRE)--Mar. 5, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced the grants of inducement restricted stock units (“RSUs”) to
PRINCETON, N.J. --(BUSINESS WIRE)--Feb. 23, 2021-- UroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the following virtual conferences in
Collaboration will focus on UGN-302 as an investigational treatment for high-grade non-muscle invasive bladder cancer PRINCETON, N.J. & HOUSTON --(BUSINESS WIRE)--Jan. 13, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions
PRINCETON, N.J. --(BUSINESS WIRE)--Jan. 6, 2021-- UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that Liz Barrett , President and Chief Executive Officer,
